New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
09:02 EDTSGEN, RHHBYSeattle Genetics to receive milestone payments as Genentech advances two ADCs
Seattle Genetics (SGEN) will receive undisclosed milestone payments under its antibody-drug conjugate collaboration with Genentech, a member of the Roche Group (RHHBY). The milestones were triggered by Genentech’s advancement of two ADCs utilizing Seattle Genetics technology into phase II clinical development. The phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 and DCDS4501A each in combination with Rituxan in patients with relapsed or refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse large B-cell lymphoma.
News For SGEN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 30, 2014
08:18 EDTSGENSeattle Genetics downgraded at BofA/Merrill
As previously reported, BofA/Merrill downgraded Seattle Genetics to Underperform from Neutral. The firm said AETHERA data for interim overall survival advantage was not significant and could reinforce Adcetris' role as a salvage therapy as opposed to a frontline option. Price target lowered to $34 from $40.
07:43 EDTSGENSeattle Genetics outlook still positive, says RBC Capital
Subscribe for More Information
07:30 EDTRHHBYSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
06:16 EDTSGENSeattle Genetics downgraded to Underperform from Neutral at BofA/Merrill
September 29, 2014
13:07 EDTSGENSeattle Genetics weakness a buying opportunity, says Credit Suisse
Credit Suisse said Seattle Genetics top-line AETHERA data was significantly positive for the primary endpoint and expects full results in December at ASH to provide a meaningful update. The firm would use weakness as a buying opportunity and reiterates its Outperform rating and $51 price target.
12:59 EDTSGENSeattle Genetics positive data largely as expected, says Piper Jaffray
Piper Jaffray says the Seattle Genetics' positive top-line data from the Phase III ATHERA trial of ADCETRIS for consolidation therapy in high risk Hodgkin's lymphoma patients following stem cell transplant was largely as expected. Piper sees the potential for label expansion, but keeps an Underweight rating on the stock with a $26 price target.
08:11 EDTRHHBYRoche sees completing InterMune acquisition later today
Subscribe for More Information
06:49 EDTSGENSeattle Genetics, Takeda announce positive data from Phase 3 trial of Adcetris
Seattle Genetics and Takeda Pharmaceutical announced that patients with Hodgkin lymphoma who received ADCETRIS as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without disease progression compared to patients who received placebo. The phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL. The AETHERA trial met its primary endpoint with ADCETRIS treatment resulting in a statistically significant improvement in progression-free survival versus placebo as assessed by an independent central review committee, which equates to a 75% improvement in PFS. PFS was assessed after a minimum of two years post initiation of treatment for all study patients. A pre-specified interim analysis of overall survival showed no statistically significant difference between the treatment arms. Patients on both study arms with progression of HL received a variety of subsequent therapies. Notably, most patients on the placebo arm received ADCETRIS after progression. A further analysis of overall survival is planned in 2016.
05:47 EDTSGENSeattle Genetics to host conference call
Subscribe for More Information
05:35 EDTRHHBYExelixis announces positive results from Phase 3 pivotal trial of cobimetinib
Subscribe for More Information
September 28, 2014
12:49 EDTRHHBYRoche announces final survival results from Phase III CLEOPATRA study
Subscribe for More Information
September 26, 2014
17:59 EDTSGENSeattle Genetics up nearly 4% after hours after setting date for ADCETRIS data
September 24, 2014
10:58 EDTRHHBYRoche to host conference call
Conference call to discuss new clinical data on Roche's oncology products and pipeline that were presented at the European Society for Medical Oncology's Annual Meeting will be held on September 29 at 4 am. Webcast Link
09:07 EDTSGENSeattle Genetics reports additional data from Phase 1 trial of ADCETRIS
Subscribe for More Information
September 22, 2014
19:23 EDTRHHBYRoche management to meet with JPMorgan
Subscribe for More Information
13:53 EDTRHHBYRoche launches $5.75B bond to back InterMune acquisition, Reuters reports
Subscribe for More Information
September 20, 2014
15:43 EDTRHHBYInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information
September 17, 2014
11:00 EDTRHHBYRoche CEO rules out megadeals, focused on bolt-on acquisitions, WSJ says
Roche CEO Severin Schwan said the company won't change its acquisition strategy following the recent deals made or abandoned in the pharmaceutical sector, reports the Wall Street Journal. In an interview with WSJ, Shwan said, "We have been very consistent in our approach to M&A." Regarding transformational deal-making, he said, "We have no intention to do that, whatever happens in the industry." Reference Link
07:43 EDTRHHBYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
07:31 EDTRHHBYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use